Sapient is a biomarker discovery organization providing multi-omics services for metabolomics, lipidomics, and proteomics data generation and analysis.

Sapient Bioanalytics

Biomarker Plus is an ISO 9001:2015 certified provider of biological samples with a team of qualified professionals and over 5 years of experience in biobanking and preclinical research. The company collaborates with numerous leading medical institutions in Ukraine and provides various clinical trial services.

Biomarker Plus

Sapient Bioanalytics provides multi-omics services for biomarker discovery, including metabolomics, lipidomics, and proteomics data generation and analysis, self-described as focusing on rapid biocomputational analysis and innovative methods.

Sapient | 7,776 followers on LinkedIn. Discover dynamic biomarkers beyond the genome. | Sapient is a biomarker discovery organization providing bespoke services for metabolomics, lipidomics, and proteomics data generation and analysis, enabling biopharma sponsors to go beyond the genome to accelerate precision drug development.

Using state-of-the-art, high-throughput mass spectrometry technologies, Sapient enables nontargeted multi-omics measurements to capture thousands of dynamic biomarkers – including metabolites, lipids, and proteins – across thousands of samples at a time.

These technologies are leveraged within a larger discovery infrastructure that includes a comprehensive biocomputational framework for analysis of large-scale, multi-omics data; robust quality control analysis; and mapping of key biomarker-phenotype associations.

CxO | Ex-McKinsey | PE Advisor | Pharma AI

Jonathan Usuka

People Partner * Culture Creator & Ambassador * Change Agent * Talent Coach * Status Quo Disrupter

Julia Stevens

Senior Scientist at Karolinska Institutet and consultant in Computational Biology and Data Science

Roland Nilsson

Business Development l Marketing l Life Sciences l Biotechnology l Diagnostics l Multi-omics

Tom Vojtko

Sapient

Today is #WorldDiabetesDay : a great opportunity to raise awareness to improve prevention, diagnosis, and management of diabetes mellitus, and to highlight the exciting science that is helping to drive these initiatives forward for public health. Multifactorial conditions such as diabetes require comprehensive characterization for proper diagnosis and treatment. This recent review shows the power of #multiomics to identify novel diabetes mellitus #biomarkers , compiling results from numerous papers that have applied omics to elucidate early biomarkers and new diagnostic techniques for type 1 diabetes (T1D), type 2 diabetes (T2D), and gestational diabetes mellitus (GDM). https://lnkd.in/gPsZHMBh At Sapient, we're proud to contribute to #diabetes research & drug development through the discovery of dynamic metabolite, lipid, and protein biomarkers that improve early disease prediction, diagnosis, patient stratification, and drug response monitoring. We'll continue to work to accelerate these discoveries that can reduce risk of diabetes and improve quality of life for those with the disease.

Thank you to Bruker for inviting us to speak at the Life Science Mass Spec Users Meeting on using #multiomics data to accelerate drug discovery. Many great questions were asked by the audience and there is clear interest and opportunity in leveraging #massspectrometry methods to enable both broad-scale and targeted #proteomics , #metabolomics , and #lipidomics for drug development. If you have questions on how these approaches can be applied in your studies, reach out to set a time to talk!: https://lnkd.in/grcp4BZg

#Didyouknow ? Sapient’s 𝐅𝐚𝐭𝐭𝐲 𝐀𝐜𝐢𝐝𝐬 𝐏𝐚𝐧𝐞𝐥 captures up to 34 fatty acids and conjugates, enabling rapid biomarker profiling and fast time-to insight to accelerate your study. Fatty acids influence cell and tissue metabolism and function, and while traditionally linked to #cardiovascular disease, these molecules have also been found to associate with a range of other diseases, from type 2 #diabetes to inflammatory conditions to #cancer . Request this ready-to-order panel for your study: https://lnkd.in/g8GD3gM7

There's still time to join us for this exciting #MultiOmics Symposium! This is your chance to hear from a diverse range of speakers – from pharmaceutical developers to leading researchers to technology innovators – on how multi-omics approaches are making an impact in their studies. We'll be presenting alongside experts from: • Boehringer Ingelheim • Arizona State University • Nanostring / Bruker Spatial Biology • The Institute of Cancer Research, London • Codetta Bio • SciLifeLab Sign up to attend! https://lnkd.in/g5z6XM3F [you can also register to receive the recordings on-demand post event]

What was it about the promise of greater #biomarker discovery that drove Sapient's founder Mo Jain, MD PhD to leave his tenured position and pursue the commercialization of his lab's mass spectrometry innovations for drug development? Biocom California shares the story in their latest #LifeLines Spotlight featuring Dr. Jain and the exciting strides that Sapient has made in advancing #multiomics beyond the genome to benefit pharma companies, researchers, and patients globally. Read the full article here: https://lnkd.in/gc-YvD-m

#Proteindegraders like PROTACs and molecular glues have the potential to significantly expand the druggable space. Effective development of these therapies demands a method that is optimized to broadly screen degrader molecules for target selectivity as well as for deep profiling of chosen degraders across different cell lines, drugs, doses, and time points. Learn how mass spectrometry-based 𝐏𝐫𝐨𝐭𝐞𝐢𝐧 𝐃𝐞𝐠𝐫𝐚𝐝𝐞𝐫 𝐏𝐫𝐨𝐭𝐞𝐨𝐦𝐢𝐜𝐬 enables both: • High throughput cell-based screening of thousands of degrader compounds for a target of interest, and • Deep proteome profiling to comprehensively assay selected protein degraders, including assessment of on-target and off-target effects https://lnkd.in/gBbuXAMU

We are very excited to participate in this symposium and the conversations that are integral to moving #multiomics and #precisionmedicine forward. Check out more highlights of the agenda and how to register to join us! 🔽 https://lnkd.in/g7YszD7b

In what key areas can mass spectrometry-based #proteomics and #metabolomics add insight value for drug development? In a recent interview with PharmaShots , Sapient's Dr. Jonathan Usuka shares examples of how these approaches are being applied across phases, from early discovery including target identification and high throughput drug screening to preclinical translation and in #clinicaltrials . Watch the clip below and access the full video to hear more: https://lnkd.in/gACSMepi

Join this inaugural 𝐯𝐢𝐫𝐭𝐮𝐚𝐥 𝐌𝐮𝐥𝐭𝐢-𝐎𝐦𝐢𝐜𝐬 𝐒𝐲𝐦𝐩𝐨𝐬𝐢𝐮𝐦 on November 12, presented by Oxford Global , to hear how delegates across pharma, biotech, and academia are leveraging #multiomics technologies and techniques to amplify #biomarker discovery and toward the development of precision medicines. From presentations to collaborative panels, the symposium will bring together scientific and technological innovators for focused conversations on multi-omics advancements in drug development, including topics such as: ➡️ Inflammatory Disease Biomarker Development Using Omics Approaches ➡️ Next-Generation Multi-Omics to Amplify Drug Development Insights ➡️ Single Cell Spatial Proteomics & Transcriptomics ➡️ Multimodal Analysis Towards Biomarker Complexity Learn more about Sapient's featured presentation and panel, and secure your spot!: https://lnkd.in/gHFYrBwZ

Multifaceted diseases like #CKD present significant challenges in both diagnosis and management, necessitating a more nuanced approach for effective treatment. Existing classification systems used to subtype CKD by disease severity are known to be imprecise, and are based on the degree of kidney damage that has already occurred rather than risk factors, particularly for early- vs. late-onset disease. We explore how the use of dynamic #biomarkers discovered via nontargeted approaches can provide new value in understanding the heterogeneous disease biology of CKD, to better predict disease progression and subtype patients by risk factors beyond #genetics : https://lnkd.in/gehzdWt4

Metric
Company Name	Sapient Bioanalytics	Biomarker Plus
Symbol
MSH ID	BIO:SAPIENT	COM:BIOMARKERPLUS
Market	PRIVATE	PRIVATE
Sector	Healthcare & Health Services	Healthcare & Health Services
Industry	Biotechnology	Clinical Research
Country	US	UA
Stage	Grant
Employee Count
Website	sapient.bio	biomarkerplus.com
LinkedIn	sapientbio	biomarker-plus
Founders

Metric
Market Cap
Enterprise Value
Monthly Web Traffic	1.13K
Web Traffic Growth	2.05
Valuation
Raised Capital	9.20M

Metric
Revenue
Revenue (LTM)
Revenue (NTM)
Gross Profit
EBITDA
Operating Income
Net Income
EPS
Diluted EPS
Revenue 2022
Revenue 2023
Revenue 2024
Revenue 2025
Revenue 2026

Metric
Revenue Growth (LTM)
Revenue Growth (NTM)
Gross Profit Growth (LTM)
EBITDA Growth (LTM)
Net Income Growth (LTM)
14-Day Growth Score
28-Day Growth Score
90-Day Growth Score
365-Day Growth Score

Metric
Gross Profit Margin
Operating Profit Margin
EBITDA Margin
Net Profit Margin
Return on Equity
Return on Assets
Return on Capital Employed

SAPI

BIO:SAPIENT

Sapient Bioanalytics

Company Overview

Market Metrics

Financial Performance

Growth Metrics

Profitability Ratios

Valuation Multiples

Operational Metrics

Cash Flow Metrics

Balance Sheet Metrics

Efficiency Metrics

Metric
P/E Ratio
P/B Ratio
Revenue Multiple (LTM)
Revenue Multiple (NTM)
EBITDA Multiple (LTM)
EBITDA Multiple (NTM)
Price to Sales Ratio
EV Multiple

Metric
Days Sales Outstanding
Days Payables Outstanding
Days Inventory Outstanding
Operating Cycle
Cash Conversion Cycle
Asset Turnover

Metric
Operating Cash Flow
Free Cash Flow
Cash Flow to Debt
Operating Cash Flow/Sales
Free Cash Flow Yield

Metric
Cash & Equivalents
Accounts Receivable
Inventory
Goodwill
Debt to Capitalization
Debt to Assets
Current Ratio
Quick Ratio

Metric
Rule of 40 (LTM)
Rule of 40 (NTM)
Stock Comp to Revenue
R&D to Revenue
SG&A to Revenue